Metraipolis › archive › dc_82841ef15db3

Use of Glucagon-Like Peptide-1 (GLP-1) Agonists in Modulating Preexisting Dermatologic Disease: A Systematic Review — Europe PMC PMID:41020015

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41020015
DOI
10.7759/cureus.93282
License (as archived)
solo-consultazione
Archived
2026-11-09T18:10:24.998Z
SHA-256 of the archived text
cb50bf641f738b83de05486919bbd075249b63726ad48cc3210c95f27fc93220
Stable URL of this page
https://metraipolis.com/documento/dc_82841ef15db3

How to cite

Use of Glucagon-Like Peptide-1 (GLP-1) Agonists in Modulating Preexisting Dermatologic Disease: A Systematic Review — Europe PMC PMID:41020015 — Europe PMC (en), https://europepmc.org/article/MED/41020015 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_82841ef15db3 (Metraipolis archive dc_82841ef15db3, sha256 cb50bf641f738b83de05486919bbd075249b63726ad48cc3210c95f27fc93220)
BibTeX
@misc{dc82841ef15db3,
  title = {Use of Glucagon-Like Peptide-1 (GLP-1) Agonists in Modulating Preexisting Dermatologic Disease: A Systematic Review — Europe PMC PMID:41020015},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41020015},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_82841ef15db3; sha256 cb50bf641f738b83de05486919bbd075249b63726ad48cc3210c95f27fc93220},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41020015. Agents can read the archived copy with the MCP tool read_document.